{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/smoking-cessation/prescribing-information/varenicline/","result":{"pageContext":{"chapter":{"id":"0bf318c3-08dc-5d92-a4d3-2a76e6dcacff","slug":"varenicline","fullItemName":"Varenicline","depth":2,"htmlHeader":"<!-- begin field 8e7ae79f-e0e2-42c6-9d3e-2a7d6c4e001f --><h2>Varenicline</h2><!-- end field 8e7ae79f-e0e2-42c6-9d3e-2a7d6c4e001f -->","summary":"","htmlStringContent":"<!-- begin item 9fb39894-9eab-4886-9a14-d1a19d40a1f0 --><!-- end item 9fb39894-9eab-4886-9a14-d1a19d40a1f0 -->","topic":{"id":"ebf6cee5-5af1-52b6-be36-ffbde79ca62f","topicId":"d067f8f3-0954-4f6f-aa2d-7367538e4d66","topicName":"Smoking cessation","slug":"smoking-cessation","lastRevised":"Last revised in November 2020","chapters":[{"id":"0061c5ae-dd4a-5d21-b48c-668fde7b2792","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6d1d5418-f561-5af6-b8c6-fc662f3ed1a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4153a516-b9c3-5ccd-b0dc-802eec6e791e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8e76eb05-e3c6-56ff-9af2-254532c75b13","slug":"changes","fullItemName":"Changes"},{"id":"3c6ceb58-b810-5e70-839f-8509aaafe066","slug":"update","fullItemName":"Update"}]},{"id":"ea4cf1db-781d-5517-8878-d38a96f2d1c5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bbbe94e2-fe22-5d1a-acb7-68d5e9889beb","slug":"goals","fullItemName":"Goals"},{"id":"56f5ea28-1670-53a4-a478-33a402bc7d1b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"234b7e6d-ac08-55b2-abd7-674c4643c59c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d2e91021-4127-5bfa-9129-033bc40bcab8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0e030910-df21-55ed-85f4-778b0a92a88f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"583a3a07-c973-5d68-b342-99b8e0dbeb74","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8349892f-8857-507e-b3ca-b3aedf9ff29d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"22c82094-eeb9-578d-acb1-a91b122b264b","slug":"withdrawal-symptoms","fullItemName":"Withdrawal symptoms"},{"id":"684b949d-de54-55c1-9c8c-5e29f240784d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"de278e39-c963-55cb-b3f3-f4c21c4bce92","slug":"harms-caused-by-smoking","fullItemName":"Harms caused by smoking"},{"id":"a9f396cb-609a-5ab8-b6ad-24d7084af5f5","slug":"benefits-of-stopping-smoking","fullItemName":"Benefits of stopping smoking"}]},{"id":"d491264b-2fec-55fc-8464-dc497057057c","fullItemName":"Management","slug":"management","subChapters":[{"id":"67f11ceb-acb3-546c-ba55-c7981861e6bb","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"6593a229-0a53-5e7e-94df-52f7ea3e248d","slug":"adults","fullItemName":"Scenario: Adults"},{"id":"e616e0e0-2ef7-55fb-b0a5-40a1dee23996","slug":"pregnant-or-breastfeeding","fullItemName":"Scenario: Pregnant or breastfeeding"},{"id":"39b9fd08-1dfb-5cff-a105-6964621414fc","slug":"12-17-years","fullItemName":"Scenario: 12-17 years"},{"id":"1521b61b-1fc1-505a-b1ea-4f3c6c7821e5","slug":"harm-reduction","fullItemName":"Scenario: Harm reduction"}]},{"id":"534878c5-24a6-5d55-aab1-d680da731f9c","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5385fc41-730b-5f44-b19a-162c234ba090","slug":"nicotine-replacement-therapy-nrt","fullItemName":"Nicotine replacement therapy (NRT)"},{"id":"029422cb-c063-54a5-adba-d7e2c1508a2c","slug":"bupropion","fullItemName":"Bupropion"},{"id":"0bf318c3-08dc-5d92-a4d3-2a76e6dcacff","slug":"varenicline","fullItemName":"Varenicline"},{"id":"55631955-d4e3-58ea-92ab-c9beb61af299","slug":"drugs-affected-by-smoking-cessation","fullItemName":"Drugs affected by smoking cessation"}]},{"id":"08f5d42d-b8f6-5145-bef7-f1049e7b6e47","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4dd871a8-f5c2-5399-bbd0-e38843de9929","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"54db5fa3-0428-5365-9b73-16348c0cbc3f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7af0460f-945a-59a6-9b1a-583aab3c09b8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fe134945-3412-53ed-b798-57e958ac842c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d8a134c7-4e7c-5c14-a053-831f057b4fac","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"42f0adc0-ab3c-5a96-b5a6-0eb20614a611","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"07a973a1-96be-50d1-9ff8-17e6396e0d13","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"534878c5-24a6-5d55-aab1-d680da731f9c","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"3d1a6d02-8716-588c-a00d-aa3ce9331027","slug":"mode-of-action-of-varenicline","fullItemName":"Mode of action of varenicline","depth":3,"htmlHeader":"<!-- begin field 47d44390-4d90-4a97-b2b1-ec1b6ca19473 --><h3>Mode of action of varenicline</h3><!-- end field 47d44390-4d90-4a97-b2b1-ec1b6ca19473 -->","summary":"","htmlStringContent":"<!-- begin item 86f7cf53-5512-4c09-919f-ff0c7d4fbfa2 --><!-- begin field 17c1f012-49e6-4423-9646-f8f9e0a913f8 --><ul><li>Varenicline is a partial nicotinic receptor agonist. It alleviates symptoms of craving and withdrawal, and reduces the rewarding and reinforcing effects of smoking by preventing nicotine binding to the receptors.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">ABPI, 2018</a>] </p><!-- end field 17c1f012-49e6-4423-9646-f8f9e0a913f8 --><!-- end item 86f7cf53-5512-4c09-919f-ff0c7d4fbfa2 -->","subChapters":[]},{"id":"083b4208-8262-5c61-8bb0-6bd470bdf615","slug":"dose-duration","fullItemName":"Dose and duration","depth":3,"htmlHeader":"<!-- begin field 9000783b-8bcd-4735-895f-06eb1751bbe2 --><h3>Dose and duration </h3><!-- end field 9000783b-8bcd-4735-895f-06eb1751bbe2 -->","summary":"","htmlStringContent":"<!-- begin item aaa1b905-4ecb-4a53-b027-5a6653a13011 --><!-- begin field 21855802-82f6-4cea-98bb-a2c3a58a8335 --><ul><li>Varenicline should be started while the person is still smoking.<ul><li>Advise the person to stop smoking 7–14 days after starting varenicline.</li></ul></li><li>The recommended treatment dose is 1 mg varenicline twice daily following a 1-week titration as follows:<ul><li>Days 1–3: 500 micrograms once a day.</li><li>Days 4–7: 500 micrograms twice a day.</li><li>Day 8 onwards: 1 mg twice a day.<ul><li>For people who cannot tolerate the <a class=\"topic-reference internal-reference\" href=\"/topics/smoking-cessation/prescribing-information/varenicline/#adverse-effects\">adverse effects</a> of higher doses (1 mg twice daily) of varenicline, the dose may be reduced to 500 micrograms twice a day.</li></ul></li></ul></li><li>For people with severe renal impairment (estimated creatinine clearance less than 30 mL/min), the recommended dose is varenicline 1 mg once a day. Dosing should begin at 0.5 mg once a day for the first 3 days, then increased to 1 mg once a day.</li><li>The recommended course of treatment is 12 weeks.<ul><li>For people who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks' treatment with varenicline at 1 mg twice daily may be considered to help maintain abstinence.</li></ul></li><li>Varenicline may be stopped without tapering the dose. However, immediately after stopping treatment with varenicline, up to 3% of people experience an increase in irritability, urge to smoke, depression, or insomnia.<ul><li>Consider tapering the dose in these people. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">BNF 75, 2018</a>]</p><!-- end field 21855802-82f6-4cea-98bb-a2c3a58a8335 --><!-- end item aaa1b905-4ecb-4a53-b027-5a6653a13011 -->","subChapters":[]},{"id":"c6811bae-6f31-53b9-95e1-eff4e20a8bd6","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 60a3d1bc-2fa2-47d1-bb55-9c2c423be3b9 --><h3>Contraindications and cautions</h3><!-- end field 60a3d1bc-2fa2-47d1-bb55-9c2c423be3b9 -->","summary":"","htmlStringContent":"<!-- begin item 092c2b6c-aff6-40e7-a94a-a3a63ce7fb9b --><!-- begin field 3e7fcb47-0a5d-4261-a743-ec01c6a40c5f --><ul><li><strong>Do not prescribe varenicline to people:</strong><ul><li>Aged under 18 years. </li><li>With end-stage renal disease.</li></ul></li><li><strong>Prescribe varenicline with caution to people with:</strong><ul><li>A history of cardiovascular disease.</li><li>A history of psychiatric illness.</li><li>Epilepsy, or a predisposition to seizures. </li><li>Moderate renal impairment (creatinine clearance [CrCl] 30–50 mL/min) — for people who experience adverse reactions that are not tolerable, reduce dose to 1 mg once daily.</li><li>Severe renal impairment (CrCl less than 30 mL/min) — the starting dose is 0.5 mg once a day for the first 3 days, then 1 mg once daily.   </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">BNF 75, 2018</a>]</p><!-- end field 3e7fcb47-0a5d-4261-a743-ec01c6a40c5f --><!-- end item 092c2b6c-aff6-40e7-a94a-a3a63ce7fb9b -->","subChapters":[]},{"id":"cf3f9d9f-88db-569a-8014-fa1b819a243c","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 2504d3f8-f73d-4d04-9def-5055af1d560d --><h3>Adverse effects</h3><!-- end field 2504d3f8-f73d-4d04-9def-5055af1d560d -->","summary":"","htmlStringContent":"<!-- begin item c822caff-5a75-4b27-9467-786e133cf3b2 --><!-- begin field dd271026-676b-43dc-999f-1440c1077c17 --><ul><li><strong>Adverse effects of varenicline include: </strong><ul><li><strong>Cardiac </strong>— myocardial infarction, angina pectoris, tachycardia, palpitations (uncommon).<ul><li><strong>Rarely: </strong>atrial fibrillation, ST segment depression, T wave amplitude decreased.</li></ul></li><li><strong>Gastrointestinal</strong> — nausea (very common); vomiting, constipation, diarrhoea, abdominal distension and discomfort, dyspepsia, flatulence, dry mouth (common).<ul><li><strong>Rarely:</strong> haematemesis, abnormal faeces. </li></ul></li><li><strong>Nervous system — </strong>headache (very common); somnolence, dizziness, dysgeusia (common).<ul><li><strong>Rarely: </strong>cerebrovascular accident, hypertonia, dysarthria, coordination abnormal, hypogeusia.</li></ul></li><li><strong>Psychiatric </strong>— abnormal dreams, insomnia (very common); suicidal thoughts and behaviours, aggression, panic reaction, restlessness, depression, anxiety, hallucinations (uncommon).<ul><li><strong>Rarely</strong>: psychosis, somnambulism, abnormal behaviour, dysphoria, bradyphrenia.</li><li><strong>Note: </strong>people should be advised that if serious neuropsychiatric symptoms occur while taking varenicline, it should be discontinued and they should contact a healthcare professional for re-evaluation of treatment.</li></ul></li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Arthralgia, myalgia.</li><li>Bronchitis, nasopharyngitis, fungal infection.</li><li>Chest pain.</li><li>Dyspnoea, cough.</li><li>Fatigue.</li><li>Rash, pruritus, Stevens-Johnson syndrome, erythema multiforme, angioedema.</li><li>Tinnitus.</li><li>Visual disturbances. </li><li>Weight increases, appetite changes, hyperglycaemia, diabetes mellitus.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">BNF 75, 2018</a>]</p><!-- end field dd271026-676b-43dc-999f-1440c1077c17 --><!-- end item c822caff-5a75-4b27-9467-786e133cf3b2 -->","subChapters":[]},{"id":"ea194411-dc26-5fb2-9e86-760b0a744c05","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 9f1fa953-3f0b-4c45-98b4-a283f8b30f42 --><h3>Drug interactions</h3><!-- end field 9f1fa953-3f0b-4c45-98b4-a283f8b30f42 -->","summary":"","htmlStringContent":"<!-- begin item 515bc606-a68c-4e98-8d74-12781d1cc25a --><!-- begin field a2fbefae-2613-4bfa-ad2e-90aab188d44b --><ul><li>There are no known clinically relevant drug interactions with varenicline.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">BNF 75, 2018</a>]</p><!-- end field a2fbefae-2613-4bfa-ad2e-90aab188d44b --><!-- end item 515bc606-a68c-4e98-8d74-12781d1cc25a -->","subChapters":[]},{"id":"9e18b214-5b35-5aea-a4f1-015ca663712b","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field abbb0c94-f01b-4c86-8638-a8a901061c75 --><h3>Pregnancy and breastfeeding</h3><!-- end field abbb0c94-f01b-4c86-8638-a8a901061c75 -->","summary":"","htmlStringContent":"<!-- begin item 5d4bc7b5-9df8-41cc-be8d-a8a901061b65 --><!-- begin field e46ad8ec-5f39-46ac-ae3d-a8a901061c75 --><h4>Pregnancy</h4><ul><li>The manufacturer advises that varenicline should be avoided in women who are pregnant.</li></ul><h4>Breastfeeding</h4><ul><li>It is unknown whether varenicline is excreted in breastmilk — it should be avoided in women who are breastfeeding. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">BNF 75, 2018</a>]</p><!-- end field e46ad8ec-5f39-46ac-ae3d-a8a901061c75 --><!-- end item 5d4bc7b5-9df8-41cc-be8d-a8a901061b65 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}